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Statin-Induced Diabetes: Will It Change
Clinical Practice?
A
n increase in the incidence of phy-
sician-diagnosed diabetes with ro-
suvastatin in Justiﬁcation for the
Use of Statins in Primary Prevention: an
Intervention Trial Evaluating Rosuvasta-
tin (JUPITER) published recently revived
clinical interest in the effects of statins on
glycemic control. The study showed that,
after almost 2 years of follow-up in men
and women with elevated levels of high-
sensitivity C-reactive protein but average
LDLcholesterol,rosuvastatintherapywas
associated with a mild but signiﬁcant in-
crease in the identiﬁcation of new-onset
diabetes (3% in the statin arm, 2.4% in
the placebo arm; P  0.01) (1). The po-
tential association between statin use and
new-onset diabetes gained attention in
2001 when a post hoc analysis of another
primary prevention statin trial, the West
of Scotland Coronary Prevention Study
(WOSCOPS), reported that treatment
with pravastatin decreased the hazard of
developing type 2 diabetes by 30% (haz-
ard ratio 0.7 [95% CI 0.5–0.99]; P 
0.042) (2). These seemingly contradic-
tory ﬁndings ﬂank results from four other
statin trials that failed to uncover a signif-
icant relationship between statin use and
incident type 2 diabetes when the latter
was evaluated as a tertiary end point
(3–6).
In this issue of Diabetes Care, Raj-
pathak et al. (7) bring together six ran-
domized placebo-controlled trials to
explore diabetes risk with statins using a
meta-analytical approach. The authors
found that, if they included all six studies
in the analysis (a total of 2,082 cases of
incident diabetes in 57,593 study partic-
ipants), there was no signiﬁcant associa-
tion between statin use and the
development of type 2 diabetes (relative
risk 1.06 [95% CI 0.93–1.25]). On the
other hand, when they excluded the
WOSCOPS data from the hypothesis-
testing meta-analysis, an approach fa-
vored by some (8), a small increase in
diabetes risk was found (1.13 [1.03–
1.23]).
This meta-analysis and one that pre-
cededtheresultsfromJUPITER(9)found
thatinclusionofdatafromthepravastatin
trial(s) introduced statistical heterogene-
ity. Because of their broader aims, meta-
analyses commonly involve trials with
differences in treatment regimen, patient
characteristics, duration of follow-up,
and outcome deﬁnition, differences that
must be understood to interpret the re-
sults adequately (10). Experimental stud-
ies in cell culture and animal studies, as
well as observations from clinical trials,
suggest that there are differences among
the various statins on insulin sensitivity
and glycemic control, differences that
could account for the heterogeneity ob-
served in the meta-analysis (11–14). Im-
portant differences in the design of the
statin trials analyzed, with varying peri-
odsofobservation(1.9–6.0years)andan
inconsistent deﬁnition of incident diabe-
tes, likely contribute to heterogeneity. Fi-
nally, differences in the characteristics of
the subjects studied may impact the eval-
uation of statin-associated metabolic ef-
fects (15). In fact, Rajpathak et al. (7)
found that sex, but not age, accounted for
some of the study’s heterogeneity.
WOSCOPS was the only one of the six
trials analyzed that did not enroll female
participants (2). In contrast, 38% of par-
ticipants in JUPITER were women (1).
Differencesinoverweightandobesityand
in the proportion of subjects with im-
paired fasting glucose across studies also
need to be explored because they could
well explain the heterogeneity observed
in the meta-analysis and account for the
differentialeffectofstatinsonincidentdi-
abetes. For instance, baseline fasting glu-
cose in WOSCOPS averaged 85 mg/dl; in
the Long-Term Intervention with Prava-
statin in Ischemic Disease (LIPID) study,
mean fasting glucose was 93.6 mg/dl in
subjects with normal glucose tolerance
and 113 mg/dl in participants with im-
paired glucose tolerance (2,5). BMI
among subjects in WOSCOPS averaged
25.9 kg/m
2, whereas the mean or median
BMI among subjects in the Heart Protec-
tion Study (HPS), Controlled Rosuvasta-
tin Multinational Trial in Heart Failure
(CORONA), and JUPITER was above 27
kg/m
2 (1,2,6).
Is the association between statin use
and new-onset diabetes plausible? Many
mechanistic and experimental studies,
mostly with lipophilic statins, support
this association. Atorvastatin, but not
pravastatin, decreases glucose uptake in
adipocyte cell lines (13) and is associated
with an increase in A1C in hypercholes-
terolemic patients (12). Simvastatin, but
not pravastatin, was shown to decrease
insulin sensitivity and adiponectin levels
inasmallrandomizedplacebo-controlled
study (16). Simvastatin and atorvastatin,
but not pravastatin, have been shown to
decrease insulin secretion in -cells (14).
On the other hand, a short-term clinical
trial comparing rosuvastatin with atorva-
statin in subjects with metabolic syn-
drome showed no signiﬁcant differences
in fasting glucose and in homeostasis
model assessment–insulin resistance
(HOMA-IR) at 6 weeks between the
statins and placebo groups (17). The in-
hibition of isoprenoid synthesis may ex-
plain some of the dysglycemic effects
observed with statins (13).
If future studies were to conﬁrm that
some or all of the statins are associated
with an increased risk for incident diabe-
tes, would it change current clinical prac-
tice? Would increases in glycemia be
clinically acceptable in the context of the
beneﬁtconferredbytheuseofthesemed-
ications? We have learned from other tri-
als that improvement of surrogate
markers does not necessarily translate
into clinical beneﬁt (18). It is well estab-
lished that in people at increased cardio-
vascular risk, with and without diabetes,
statins provide substantial beneﬁt by de-
creasingtheincidenceofmajorcardiovas-
cular events and overall mortality. Post
hoc analyses have suggested that in high-
risk subjects without diabetes, it is those
with features of the metabolic syndrome
who derive a greater beneﬁt from statin
use (19).
The development of diabetes is of
clinical concern because of the risk of its
associatedcomplications.Becausecardio-
vascular disease accounts for almost two-
thirds of deaths in people with diabetes,
the protective effect of statins on this ma-
jor complication may sufﬁce to support
their use despite a potential risk of new-
onset diabetes. What about the effects of
statinsonmicrovasculardisease?Arecent
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(20)showedthatstatin-inducedincreases
in glycemia were mild. Within a 2-year
period of follow-up, fasting plasma glu-
cose increased from 98 to 105 mg/dl in
statin users without diabetes and from 97
to 101 mg/dl in their non–statin-using
counterparts. In subjects with diabetes,
the observed increases were from 102 to
141 mg/dl in statin users and from 100 to
129 mg/dl in nonusers. Although hyper-
glycemia is strongly associated with the
development of microvascular complica-
tions, evidence is accumulating to sup-
port the notion that dyslipidemia may
also play a role and that statins may im-
prove microvascular function (21). Small
studies in dyslipidemic patients with dia-
betes have shown that statins may retard
theprogressionofretinopathyandreduce
the severity of hard exudates and sub-
ﬂoveal lipid migration (21–23). Likewise,
experimental and clinical studies support
an association between dyslipidemia and
the progression of renal disease and the
beneﬁtofstatinsonnephropathy(21,24).
The evidence for a protective role of
statins in neuropathy is more limited but
encouraging (25). Overall, there is evi-
dence to suggest that lipid lowering and
statin use may have microvascular bene-
ﬁts, but further evidence from random-
ized controlled trials is needed.
The study by Rajpathak et al. (7)
keeps alive the intriguing notion that st-
atins may impact insulin sensitivity and
glycemia. As with other meta-analyses,
the results are only hypothesis generating
because they rely on data published pre-
viously and thus are inherently observa-
tional. However, and more importantly,
the study by Rajpathak et al. brings to our
attentionhowlittleweknowaboutstatins
beyond their beneﬁt on macrovascular
disease, speciﬁcally the need for random-
ized clinical trials to evaluate the role of
statins on microvascular outcomes. If
statins reduce macrovascular and micro-
vascular morbidity and mortality, the as-
sociated modest increase in glycemia will
no longer be an issue of concern.
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